Abstract 7299: CS2009: A first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFA with potential to be a next-generation backbone therapy with combined checkpoint inhibition and anti-angiogenesisChuan Wang, Jianxin Yang, Yi Sun et al.|Cancer Research|2025Cited by 4
504 CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluationChuan Wang, Jianxin Yang, Ning Zhang et al.|Regular and Young Investigator Award Abstracts|2024Cited by 0
Abstract 2954: CS5007: A novel EGFR and HER3 dual-targeted antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studiesChuan Wang, Jianxin Yang, Yamin Wang et al.|Cancer Research|2025Cited by 0
Abstract 4751: CS5005: A novel SSTR2-targeted antibody-drug conjugate (ADC) with robust antitumor activity in preclinical studiesChuan Wang, Jianxin Yang, Xinling Zhang et al.|Cancer Research|2025Cited by 0
Abstract 2953: CS5006: A novel integrin β4-targeted antibody-drug conjugate (ADC) with robust antitumor activity in preclinical studiesChuan Wang, Jianxin Yang, Yamin Wang et al.|Cancer Research|2025Cited by 0